Trump administration reaches drug-pricing deals with nine more pharmaceutical companies

What This is

• President Trump announced agreements with nine additional pharmaceutical companies, bringing the administration’s drug-pricing deals to 26 companies covering most of the U.S. market.
• The deals are built around a “most-favored-nation” approach that aims to make some U.S. prices match the lowest prices paid in other developed countries.
• A central feature is discounts for state Medicaid programs so certain outpatient drugs are sold to states at the foreign-matched price.
• Several reports say companies receive incentives such as protection from tariffs on imported patented drugs or exemptions from related Medicare pricing requirements.
• The White House says participating companies pledged about $19.6 billion in near-term U.S. manufacturing investment, and some deals include domestic production commitments.
• Some agreements include added measures such as direct-to-consumer discounts through the TrumpRx website and contributions to federal strategic reserves.
• The administration has not released full contract terms, and lawmakers and reporters have questioned how much prices will fall and who benefits.
• CSL, Australia’s largest biotech, said it will provide Medicaid discounts and price-matching for new therapies and expand a plasma-therapies plant in Illinois as part of its commitments.

Why This Matters

• If the discounts are real and broad, states could spend less on Medicaid drugs, freeing money for other health needs.
• Linking U.S. prices to what other countries pay could reshape how drug companies set prices worldwide and may affect which new drugs launch first in the U.S.
• Using tariff threats and exemptions as leverage blurs the line between health policy and trade policy, and could raise costs if companies respond by changing supply chains.
• Limited transparency makes it harder for patients, states, and Congress to verify savings, fairness, and which drugs are covered.